Robin Kate Kelley

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Figure S2 from HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma

  2026-06-17

• Figure S4 from HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma

  2026-06-17

• Figure S1 from HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma

  2026-06-17

• Figure S3 from HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma

  2026-06-17

• Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement

  Nature Reviews Clinical Oncology · 2026-06-10

• 35A phase 1/2 trial investigating ivosidenib plus nivolumab and ipilimumab in patients with previously treated mIDH1 CCA

  The Oncologist · 2026-06-01

• A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma.

  Journal of Hepatology · 2026-06-01 · 1 citations

• Abstract 2667: TM4SF1 as a novel tumor-associated antigen in biliary tract cancers targetable by immune effector cell therapy

  Cancer Research · 2026-04-03

• Abstract 3793: Preventing nk cell activation in the damaged liver induced by cabozantinib/pd-1 blockade increases survival in hepatocellular carcinoma models

  Cancer Research · 2026-04-03

• Hallmarks of liver cancer: Therapeutic implications

  Cell · 2026-04-01 · 2 citations

• Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses

  Hepatology · 2026-02-02

• 33 - ANÁLISIS DE LOS TRATAMIENTOS SUBSIGUIENTES ANTINEOPLÁSICOS DEL ESTUDIO DE FASE 3 HIMALAYA: TREMELIMUMAB MÁS DURVALUMAB EN EL CARCINOMA HEPATOCELULAR AVANZADO O IRRESECABLE

  Gastroenterología y Hepatología · 2026-02-01

• Safety outcomes with tremelimumab (T) rechallenge in the phase 3 HIMALAYA study of T plus durvalumab (D) in unresectable hepatocellular carcinoma.

  Journal of Clinical Oncology · 2026-01-10 · 1 citations

• A phase 1, first-in-human, multicenter study of ZW251, a novel glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in participants with hepatocellular carcinoma (HCC).

  Journal of Clinical Oncology · 2026-01-10

• Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial

  RWTH Publications (RWTH Aachen) · 2026-01-01

• Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials

  Cancer · 2025-12-19 · 1 citations

• Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis

  Liver Cancer · 2025-12-18 · 2 citations

• Supplementary Methods, Tables, and Figure from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study

  2025-12-09

• T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma

  Clinical Cancer Research · 2025-12-08

• Supplementary Data DS1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

  2025-11-25